174 related articles for article (PubMed ID: 21982576)
1. Auger electron emitter against multiple myeloma--targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine.
Morgenroth A; Dinger C; Zlatopolskiy BD; Al-Momani E; Glatting G; Mottaghy FM; Reske SN
Nucl Med Biol; 2011 Oct; 38(7):1067-77. PubMed ID: 21982576
[TBL] [Abstract][Full Text] [Related]
2. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines.
Reske SN; Deisenhofer S; Glatting G; Zlatopolskiy BD; Morgenroth A; Vogg AT; Buck AK; Friesen C
J Nucl Med; 2007 Jun; 48(6):1000-7. PubMed ID: 17504875
[TBL] [Abstract][Full Text] [Related]
3. Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine.
Morgenroth A; Deisenhofer S; Glatting G; Kunkel FH; Dinger C; Zlatopolskiy B; Vogg AT; Kull T; Reske SN
Clin Cancer Res; 2008 Nov; 14(22):7311-9. PubMed ID: 19010846
[TBL] [Abstract][Full Text] [Related]
4. Breaking the invulnerability of cancer stem cells: two-step strategy to kill the stem-like cell subpopulation of multiple myeloma.
Morgenroth A; Vogg AT; Zlatopolskiy BD; Siluschek M; Oedekoven C; Mottaghy FM
Mol Cancer Ther; 2014 Jan; 13(1):144-53. PubMed ID: 24174494
[TBL] [Abstract][Full Text] [Related]
5. Rationale of 5-(125)I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker.
Toyohara J; Hayashi A; Sato M; Tanaka H; Haraguchi K; Yoshimura Y; Yonekura Y; Fujibayashi Y
J Nucl Med; 2002 Sep; 43(9):1218-26. PubMed ID: 12215562
[TBL] [Abstract][Full Text] [Related]
6. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
8. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma effects of a sesquiterpene lactone parthenolide.
Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
[TBL] [Abstract][Full Text] [Related]
10. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and metabolism of 5-125I-iodo-4'-thio-2'-deoxyuridine in rodents.
Toyohara J; Gogami A; Hayashi A; Yonekura Y; Fujibayashi Y
J Nucl Med; 2003 Oct; 44(10):1671-6. PubMed ID: 14530485
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
14. Erucylphospho-N,N,N-trimethylpropylammonium shows substantial cytotoxicity in multiple myeloma cells.
Yosifov DY; Konstantinov SM; Berger MR
Ann N Y Acad Sci; 2009 Aug; 1171():350-8. PubMed ID: 19723075
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
[TBL] [Abstract][Full Text] [Related]
16. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Ishitsuka K; Hideshima T; Hamasaki M; Raje N; Kumar S; Podar K; Le Gouill S; Shiraishi N; Yasui H; Roccaro AM; Tai YZ; Chauhan D; Fram R; Tamura K; Jain J; Anderson KC
Oncogene; 2005 Sep; 24(38):5888-96. PubMed ID: 15940263
[TBL] [Abstract][Full Text] [Related]
17. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
18. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Goel A; Dispenzieri A; Greipp PR; Witzig TE; Mesa RA; Russell SJ
Exp Hematol; 2005 Jul; 33(7):784-95. PubMed ID: 15963854
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog signaling sensitizes glioma stem cells to endogenous nano-irradiation.
Morgenroth A; Vogg AT; Ermert K; Zlatopolskiy B; Mottaghy FM
Oncotarget; 2014 Jul; 5(14):5483-93. PubMed ID: 24978848
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I (IGF-I) stimulates proliferation but also increases caspase-3 activity, Annexin-V binding, and DNA-fragmentation in human MG63 osteosarcoma cells: co-activation of pro- and anti-apoptotic pathways by IGF-I.
Raile K; Hille R; Laue S; Schulz A; Pfeifer G; Horn F; Kiess W
Horm Metab Res; 2003; 35(11-12):786-93. PubMed ID: 14710359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
